tbuckley/cabot-search huggingface dataset:
Evidence for the Baby-Friendly Hospital Initiative to Support Breastfeeding—Reply
Authors: Carrie D. Patnode, Caitlyn A. Senger
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Tadpole Pupil
Authors: Kavita Aggarwal, Göran Darius Hildebrand
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8.
Authors: Rachel Catherine Jankowitz, Jame Abraham, Antoinette R. Tan, Steven A. Limentani, Laura M Adamson, Marc E. Buyse, Samuel A. Jacobs, Norman Wolmark
Journal: Journal of Clinical Oncology (2012)

611 Background: Dual blockade of ErbB receptors combined with chemotherapy compared with single-agent blockade improves efficacy in HER2-positive disease. FB-8 is single arm, Phase I dose-escalation study to determine safety and tolerability of weekly paclitaxel (P), the irreversible tyrosine kinase inhibitor, neratinib (N) and trastuzumab (T) in women with metastatic, HER2-positive breast cancer (MBC). Methods: Women with measurable or non-measurable MBC (ECOG PS 0 - 2) received P (80 mg/m2 IV days 1, 8, 15 of 28-day cycle), T (4 mg/kg IV, then 2 mg/kg IV weekly), and N (oral, daily). N was dose-escalated using 3+3 design at 120 mg, 160 mg, and 240 mg, dose-limiting toxicity (DLT) determined in cycle 1. All patients (pts) received prophylactic anti-diarrheals. Results: All pts were taxane and trastuzumab pre-treated, with mean of 4 prior regimens. At N=120 mg, there was 1 DLT, grade (gr) 3 diarrhea with dehydration. Three more pts were enrolled; none experienced DLT. At N=160 mg, there were no DLTs. At N=240 mg, 2 of 3 pts had DLTs: one gr 3 diarrhea and dehydration, one gr 3 diarrhea, dehydration, and gr 3 mucositis. After de-escalation to N=160 mg, 3 more pts were added. If N=160 mg is well tolerated, a 200 mg cohort is planned. 12 pts completed cycle 1. Efficacy data are available on 10: CR 1, PR 3, SD 1 (8+months). One pt* had resolution of non-target disease (skin and breast mass). 4 pts were off-study before the first scan (DLT 3 and progressive disease 1) and are considered non-responders (NR). The most frequent grade 3-4 adverse event was diarrhea, 3 pts. Conclusions: Dual anti-HER blockade with N, T combined with P is tolerable and highly active in pts pre-treated with anti-HER2 agents and chemotherapy. This combination will be studied in a phase II neoadjuvant breast cancer trial (NSABP FB-7). We thank Pfizer, Inc and Puma Biotechnology, Inc for their support. [Table: see text]
The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry
Authors: Ombretta Annibali, Stefan Hohaus, Valeria Tomarchio, Paola Anticoli Borza, Maria Cantonetti, Roberta Battistini, Marco Montanaro, Federico De Angelis, Giuseppe Cimino, Francesca Palombi, Anna Marina Liberati, Elisabetta Abruzzese, Cristiano Tesei, Maria Chiara Tisi, Eleonora Alma, Giuliana Rizzuto, Livio Pupo, Valerio Zoli, Elena Maiolo, Michela Ansuinelli, Virginia Naso, Maria Paola Bianchi, Maria Christina Cox
Journal: Blood (2016)
Abstract P6-07-19: An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients
Authors: E-S Lee, J Kim, T-K Yoo, Y Kim, J Han, YJ Kang, J Choi, J Rhu, H-B Lee, W Han, D-Y Noh, H-G Moon
Journal: Cancer Research (2017)

Abstract Purpose We aimed to identify whether hormonal receptors change throughout tumor progression, because this may influence management and influence prognosis in breast cancer patients. Patients and Methods From the institution's database, we collected data of 963 patients who developed relapse during their follow-ups. To determine estrogen receptor(ER) and progesterone receptor (PR), we retrospectively reviewed immunohistochemical(IHC) results in both primary and relapsed tumors. Results Among a total of 963 patients, 280 and 683 patients experienced locoregional relapse only and distant metastasis irrespective of locoreginal relapse, respectively. ER in 650 patients and PR in 590 patients from both primary tumor and relapse were identified, revealing a change in 157 (24.2%) and 154 (26.1%) patients, respectively. In patients with distant metastasis, assessment of ER and PR showed an alteration in 86 and 56 patients, respectively. The overall survival related to the change of ER and PR status in primary tumor and relapse was significantly different (log rank, P&amp;lt;0.001 in both ER and PR status). In addition, women with hormone receptors negative primary tumors that changed to hormone receptors positive tumors who received anti-hormonal therapy after relapse showed a statistically significant good overall survival (p&amp;lt;0.001) compared with women who had constant ER-negative tumors.(cox regression, hazard ratio 2.32 ; 95% CI, 1.91 to 3.01) Conclusion The breast cancer showed alterations of hormone receptor status throughout tumor progression, hat were related to the strategy of treatment and significantly influences survival. Therefore, investigations of hormone receptor at relapse are essential and helpful in breast cancer patient management. Citation Format: Lee E-S, Kim J, Yoo T-K, Kim Y, Han J, Kang YJ, Choi J, Rhu J, Lee H-B, Han W, Noh D-Y, Moon H-G. An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-19.
Abstract P5-07-13: Identification of a cancer stem sell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
Authors: TA Ince, AE Witt, C-W Lee, TI Lee, DJ Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EA Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Reply
Authors: Claudio Vitali, Hal Scofield, Stephen C. Shiboski, Lindsey A. Criswell, Thomas M. Lietman, Raphaèle Seror, Marc Labetoulle, Xavier Mariette, Astrid Rasmussen, Simon J. Bowman, Caroline H. Shiboski
Journal: Arthritis & Rheumatology (2017)
Abstract P5-08-29: Trends in age shifting and decreasing mortality of female breast cancer in Taiwan with emerging molecular subset of unmet medical need: A 30-year cohort observation from Taipei Veterans General Hospital
Authors: Y-S Lin, L-M Tseng, C-Y Liu
Journal: Cancer Research (2017)

Abstract Background: Over the past thirty years, Taiwan has become a modern Asian country with an increasing incidence of breast cancer. We hypothesized that the epidemiological and demographic features of breast cancer patients in Taiwan have changed by using cohort study based on data collected from past three decades. However, despite improvement in prognosis of most breast cancer subtypes, we found that one subtype of luminal B type her-2 negative did not show significant improvement in overall survival and disease free survival from our cohort comparison. Methods:Patients with primary breast cancer diagnosed between 1979 and 2010 were identified from the cancer registry database at Taipei Veterans General Hospital, Taiwan. Three periods of time were divided (1979 to 1988, 1989 to 1998, and 1999 to 2010) and compared to determine the epidemiological changes in female breast cancer in Taiwan. Results:From 1979 to 2010, data from a total of 8417 breast cancer patients were collected. The ratio of breast cancer patients aged ≤ 35 years decreased from 13.3% in 1979 to 1988, to 10.6% in 1989 to 1998, and to 5.2% during 1999 to 2010.In the period of 1979 to 1988, 55.7% of patients were aged ≤ 50 years, and in the period of 1999-2010, only 45.7% of breast cancer patients were aged ≤ 50 yrs.From 1979-1988, ductal carcinoma in situ (DCIS) was rarely diagnosed (0.2%), and the ratio of patients who initially presented with DCIS increased to 2.9% in 1989 to 1998, and to 11.8% in 1999 to 2010. Patients diagnosed with stage I breast cancer also increased from 16.7% in 1979-1988 to 28.4% in 1999-2010.Patients diagnosed and treated in 1999-2010 (5-year overall survival: 81.7%) had a much better outcome than patients treated in 1979-1988 (5-year overall survival: 66.3%). Cohort comparison of survival outcome for breast cancer subtypes in luminal A type, luminal B type Her-2 positive, luminal B type Her-2 negative, Her-2 type, and triple negative type disclosed no improvement in both 5-year survival and 5-year disease free survival outcomes in the subtype of luminal B type Her-2 negative. Conclusions: The epidemiological features of female breast cancer in Taiwan have changed over the past thirty years. A molecular subtype of luminal B type Her-2 negative was characterized as an emerging group with unmet medical need. Citation Format: Lin Y-S, Tseng L-M, Liu C-Y. Trends in age shifting and decreasing mortality of female breast cancer in Taiwan with emerging molecular subset of unmet medical need: A 30-year cohort observation from Taipei Veterans General Hospital [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-29.
Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia
Authors: Lorenzo Falchi, Hagop M. Kantarjian, Alfonso Quintas-Cardama, Susan O'Brien, Elias J. Jabbour, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Srdan Verstovsek, Jan A. Burger, Rajyalakshmi Luthra, Jorge E. Cortes
Journal: Blood (2012)
Comprehensive Genomic Profiling for Improved Diagnosis and Therapy of Pediatric Acute Leukemias
Authors: Rachel Kobos, Jie He, Peter G Steinherz, Kevin J. Curran, Thomas M. Renaud, Christopher Forlenza, Farid Boulad, Susan Prockop, Kristina Marie Knapp, Michael Walsh, Mikhail Roshal, Lu Wang, Elli Papaemmanuil, Ahmet Dogan, Shan Zhong, Sohail Balasubramanian, Michelle Nahas, Jo-Anne Vergilio, Jeff Ross, Phil Stephens, Tariq I Mughal, Vincent A. Miller, Scott A. Armstrong, Ross L. Levine, Alex Kentsis, Neerav N Shukla
Journal: Blood (2016)
PP40. SPECIFICITY AND TOXICITY OF 5-AMINOLEVULINIC ACID (5-ALA – GLIOLAN TM) ON CORE AND INVASIVE GLIOBLASTOMA CELL POPULATIONS
Authors: Ms Katie Elizabeth Agnes Wood, Dr Maria de los Angeles Estevez-Cebrero, Dr Stuart Smith
Journal: Neuro-Oncology (2017)

INTRODUCTION: Glioblastoma multiforme (GBM) is the most common and lethal brain cancer in adults and accounts for 65% of all primary brain tumours. In our unit we routinely utilise fluorescence image guided resection with prior administration of 5-aminolevulinic acid (5-ALA) to the patient for potentially macroscopically resectable GBMs. In the GBM cells 5-ALA is metabolised to protoporphyrin IX, which emits fluorescence when it is excited with violet light, allowing the visualisation of the cancer cells for maximal resection of the tumour. This project looks at the specificity and toxicity of 5-ALA in vitro when characterising the cancer cells isolated from the invasive margin of the tumour. METHODS: Tumour cells are isolated from both the core and the invasive margin of GBM tumours and compared to established cell lines previously derived from the core and to differentiated neural stem cells from mouse cerebellum that were used as a “normal brain” control. Cells were cultured as monolayers, labelled with 5-ALA and analysed by fluorescence microscopy and flow cytometry to determine 5-ALA specific fluorescence. Presto blue assays were carried out to investigate potential toxicity of 5-ALA in vitro. RESULTS: All GBM cells exhibited 5-ALA specific fluorescence whilst the ratio of median fluorescence intensity observed was around 2-fold for the 5-ALA positively labelled compared to the unlabelled cells (SD: 0.51) and no significant fluorescence for the non-neoplastic brain cells. Interestingly, the GBM cells isolated from a recurrent tumour showed some autofluorescence under the microscope. 5-ALA had no toxic effect on the cells. DISCUSSION: The results gained from the fluorescence microscopy and flow cytometry analysis were extremely encouraging and showed that 5-ALA labelling of a mixed population of cells, such as samples obtained from the invasive margin of the tumour, could be used to identify the GBM cells with several downstream applications including cell separation or co-staining. In addition, the technique was found to be non-toxic, with little effect on cell proliferation.
Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015*
Authors: H Y Park, E J Lee, Y W Ryu, Y Kim, H Kim, H Lee, S J Yi
Journal: Eurosurveillance (2015)

In this report, we describe 37 MERS-CoV infection cases (1 primary, 25 secondary, 11 tertiary cases) in a single hospital in South Korea. The median incubation period was six days (95% CI: 4–7 days) and the duration between suspected symptom onset and laboratory confirmation was 6.5 days (95% CI: 4–9). While incubation period was two days longer, the duration from suspected symptom onset to confirmation was shorter in tertiary compared with secondary infections.
Liposomal doxorubicin and cisplatin as first-line chemotherapy in unresectable malignant pleural mesothelioma: A phase II study
Authors: O. Arrieta, L. A. Medina, E. Guzmán, M. A. Rios Trejo, D. Mendoza, A. Astorga Ramos, L. Martinez Barrera, N. Hernández Pedro, E. Arechaga Ocampo, J. De la Garza
Journal: Journal of Clinical Oncology (2009)

e13507 Background: Malignant pleural mesothelioma (MPM) is a poor prognosis neoplasm. Its worldwide incidence is rising but until recently chemotherapy has not been shown to be effective in its treatment. The combination of cisplatin and pemetrexed is the approved “standard” treatment in unresectable MPM. Liposomal doxorubicin (LD) consists of pegylated phospholipid- vesicles that encapsulate doxorubicin conferring minimal capture from the reticulo-endothelial system resulting in a greater serum half- life, an enhanced liposome deposition in the tumor and a lower degree of toxicity. We evaluated the combination of LD and Cisplatin (Cis) in chemonaive patients with unresectable MPM. Methods: From September 2006 to October 2008, consecutive patients with stage III / IV MPM were included to receive LD 40 mg/m 2 and Cis 60 mg/m 2 every 21 days for a maximum of 4 cycles. Imaging studies were performed prior and after 2 cycles to assess response. Gamma camera images (GCI) of Tc-99m-labeled LD were acquired to evaluate LD accumulation in measurable tumor tissue. Patients gave written informed consent. Results: Twenty seven patients were included, 81.5% were stage III and 18.5% were IV. According to EORTC prognostic factors, 33.3% and 66.7% had poor and good prognosis, respectively. Median age was 59.2 years (33–80). Median follow-up was of 5.2 ± 0.8 months. Median survival has not been reached. The 2-year overall survival was 52.5% ± 14.2. Median time to progression was 5.0 ± 1.1 months (CI 95%, 2.7–7.3). Overall response was 45.5%, stable disease 36.4% and progression of 18.2%. GCI showed good accumulation and retention (60%) of the labeled LD in tumor tissue at 4 h after the initial injection. There were no toxic deaths. Conclusions: Cis+LD is a highly active regimen in MPM with comparable results to the most active regimens so far reported. A phase III trial is warranted to confirm these findings. No significant financial relationships to disclose.
Tau and Cortical Thickness in Alzheimer Disease
Authors: Joseph C. Masdeu
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract P5-14-10: Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer
Authors: E Cho, Q Wu, L Rubinstein, H Linden, J Gralow, J Specht, V Gadi, G Ellis
Journal: Cancer Research (2017)

Abstract BACKGROUND: The addition of taxanes to anthracycline-based adjuvant chemotherapy has improved disease free survival (DFS) in women with high-risk early-stage breast cancer. Many studies have sought to optimize the dose intensity and density of these agents to produce improvements in outcome and tolerability. The purpose of this study was to assess the use of metronomic doxorubicin plus daily oral cyclophosphamide (AC) for 12 weeks followed by nab-paclitaxel (nP) for 12 weeks in this population. Those patients with Her2 positive disease were also given adjuvant trastuzumab. METHODS: A non-randomized phase II clinical trial was designed to (1) test the DFS at 2 years compared to historical controls, (2) assess dose intensity delivered, (3) assess use of nP in the adjuvant setting, and (4) evaluate toxicities associated with the regimen. Overall survival (OS) was a secondary outcome. The dosing of A was 24mg/m2 IV qweek and C was 60mg/m2 oral daily; nP, 100mg/m2 IV qweek. RESULTS: Sixty patients were enrolled on the study with a median follow-up of 6 years and a median age of 50 (range 30-69). 58% of patients had node positive disease. Receptor categories included hormone receptor positive (ER positive or PR positive) and HER2 negative (n=24; 40%); ER negative, PR negative, and HER2 negative (triple negative; n=19; 32%); or HER2 positive (n=17; 28%). DFS at 2 years was 93% (1 death, 3 recurrence) and at 6 years was 82%, comparable to historical controls. OS at 2 years and 6 years was 98% and 88%, respectively. Mean dose intensity was greater than 90% for AC and 88% for nP. Treatment was well-tolerated with the most common grade ≥3 toxicity being neutropenia and a 2% incidence of febrile neutropenia. Disease-free survival and overall survival at 2 and 6 years 2 year 6 year DFS %OS %DFS %OS %All patients93988288ER+ or PR+, HER2-921007979Triple negative89957989HER2+10010088100 CONCLUSSIONS: Patients achieved similar DFS to that seen in historical controls with similar rates of adverse events. Since nP dosing was 100 mg/m2, even with 88% dose intensity, the delivered taxane dose is greater than standard weekly paclitaxel. Notably disease control was particularly impressive in the triple negative subtype, which has been shown to benefit from nP over standard paclitaxel in the neoadjuvant setting in the GeparSepto (GBG 69) trial. Metronomic AC followed by nP is a safe, effective option for delivery of adjuvant chemotherapy for high-risk patients. Citation Format: Cho E, Wu Q, Rubinstein L, Linden H, Gralow J, Specht J, Gadi V, Ellis G. Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-14-10.
RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit
Authors: Ruwan Gunaratne, James Frederiksen, Nabil K. Thalji, Michelle D Ho, Gowthami M Arepally, Rodney M. Camire, Bruce A. Sullenger
Journal: Blood (2016)
Risk Factors and Outcome of Chronic GVHD: Analysis of 5,660 Patients Undergoing Unrelated Bone Marrow Transplantation through the Japan Marrow Donor Program.
Authors: Chiaki Nakaseko, Miki Nishimura, Shinnichi Ozawa, Ryuko Cho, Chikako Ohwada, Atsuo Maruta, Hisashi Sakamaki, Hiroshi Sao, Shin-ichiro Mori, Shinichiro Okamoto, Koichi Miyamura, Shunichi Kato, Tadakazu Kawase, Yasuo Morishima, Yoshihisa Kodera
Journal: Blood (2005)
Potent B Cell Leukemia-Reactive T Cells Present in Naive Donor T Cell Populations Can Be Isolated under GMP Conditions Using a Universal Stimulation and Isolation Procedure.
Authors: I. Jedema, J. Olde Wolbers, E. Steeneveld, A.-M. Rasmussen, W.M. Smit, R. Willemze, J.H. Frederik Falkenburg
Journal: Blood (2006)
Lenalidomide Is Highly Effective in Patients with Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplantation and Increases the Frequency of CD4+FOXP3+ T Cells.
Authors: Monique C. Minnema, Michael van der Veer, Tineke Aarts, Maarten Emmelot, Tuna Mutis, Henk M. Lokhorst
Journal: Blood (2007)